CRISPR Therapeutics (NASDAQ:CRSP) PT Lowered to $100.00 at Truist Financial

CRISPR Therapeutics (NASDAQ:CRSP) had its price target trimmed by Truist Financial from $120.00 to $100.00 in a report published on Monday, Benzinga reports. The brokerage currently has a buy rating on the stock.

Several other equities research analysts also recently issued reports on CRSP. Oppenheimer reduced their price objective on CRISPR Therapeutics from $102.00 to $95.00 and set an outperform rating for the company in a research note on Friday, May 10th. Stifel Nicolaus lowered their price objective on shares of CRISPR Therapeutics from $60.00 to $59.00 and set a hold rating on the stock in a research report on Tuesday, August 6th. Citigroup cut their target price on shares of CRISPR Therapeutics from $89.00 to $84.00 and set a buy rating for the company in a research report on Thursday, May 23rd. Wells Fargo & Company lowered their price target on shares of CRISPR Therapeutics from $70.00 to $65.00 and set an equal weight rating on the stock in a report on Thursday, May 9th. Finally, JMP Securities reiterated a market outperform rating and set a $86.00 price objective on shares of CRISPR Therapeutics in a report on Thursday, May 9th. Three analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat.com, CRISPR Therapeutics presently has an average rating of Hold and a consensus price target of $75.63.

CRISPR Therapeutics Stock Performance

Shares of NASDAQ:CRSP opened at $48.85 on Monday. The stock has a market capitalization of $4.15 billion, a price-to-earnings ratio of -17.96 and a beta of 1.70. CRISPR Therapeutics has a 1-year low of $37.55 and a 1-year high of $91.10. The company has a 50 day moving average price of $55.91 and a 200 day moving average price of $62.42.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings results on Monday, August 5th. The company reported ($1.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.43) by ($0.06). The company had revenue of $0.52 million during the quarter, compared to analysts’ expectations of $12.31 million. The company’s quarterly revenue was down 99.3% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.98) earnings per share. On average, sell-side analysts expect that CRISPR Therapeutics will post -5.52 EPS for the current fiscal year.

Insider Buying and Selling

In other CRISPR Therapeutics news, COO Julianne Bruno sold 3,366 shares of the business’s stock in a transaction on Friday, June 21st. The shares were sold at an average price of $56.09, for a total transaction of $188,798.94. Following the completion of the transaction, the chief operating officer now owns 6,745 shares of the company’s stock, valued at approximately $378,327.05. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 4.10% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. Creative Planning increased its position in CRISPR Therapeutics by 3.2% during the second quarter. Creative Planning now owns 14,750 shares of the company’s stock worth $797,000 after acquiring an additional 456 shares during the period. Algert Global LLC raised its position in shares of CRISPR Therapeutics by 45.0% during the second quarter. Algert Global LLC now owns 12,342 shares of the company’s stock valued at $667,000 after buying an additional 3,832 shares during the last quarter. Scientech Research LLC lifted its stake in shares of CRISPR Therapeutics by 181.6% in the second quarter. Scientech Research LLC now owns 24,323 shares of the company’s stock valued at $1,314,000 after buying an additional 15,686 shares during the period. Armistice Capital LLC lifted its stake in shares of CRISPR Therapeutics by 3.3% in the second quarter. Armistice Capital LLC now owns 198,357 shares of the company’s stock valued at $10,713,000 after buying an additional 6,357 shares during the period. Finally, Marshall Wace LLP acquired a new stake in CRISPR Therapeutics during the second quarter worth about $10,078,000. 69.20% of the stock is owned by institutional investors.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.